Skip to main content
SpringerLink
Log in

Antineoplastics

Lack of efficacy and drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wiedemann C, et al. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. Cold Spring Harbor Molecular Case Studies 8: 07 Oct 2022. Available from: URL: http://doi.org/10.1101/mcs.a006234

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics. Reactions Weekly 1934, 46 (2022). https://doi.org/10.1007/s40278-022-28427-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-28427-1

Search

Navigation